Evdokia Pasheva
Overview
Explore the profile of Evdokia Pasheva including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
221
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schroder M, Petrova M, Vlahova Z, Dobrikov G, Slavchev I, Pasheva E, et al.
Biomedicines
. 2022 Jun;
10(6).
PMID: 35740374
The successful design of antitumour drugs often combines in one molecule different biologically active subunits that can affect various regulatory pathways in the cell and thus achieve higher efficacy. Two...
2.
Schroder M, Yusein-Myashkova S, Petrova M, Dobrikov G, Kamenova-Nacheva M, Todorova J, et al.
Anticancer Agents Med Chem
. 2019 Jul;
19(15):1874-1886.
PMID: 31339077
Background: Drug resistance is a major cause of cancer treatment failure. Most cancer therapies involve multiple agents, to overcome it. Compounds that exhibit strong anti-tumor effect without damaging normal cells...
3.
Momekov G, Ugrinova I, Pasheva E, Tsekova D, Gencheva G
Int J Mol Sci
. 2018 Aug;
19(8).
PMID: 30126243
Two paramagnetic Pd complexes of hematoporphyrin IX ((7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H-23H-porphyn-2,18-dipropionic acid), Hp), namely a dinuclear one [Pd₂(Hp)Cl₃(H₂O)₅]·2PdCl₂, and a mononuclear metalloporphyrin type [Pd(Hp)Cl(H₂O)]·H₂O, have been synthesized reproducibly and isolated as neutral compounds...
4.
Yusein-Myashkova S, Stoykov I, Gospodinov A, Ugrinova I, Pasheva E
J Biochem
. 2016 Feb;
160(1):37-47.
PMID: 26896489
Elucidation of the cellular components responsive to chemotherapeutic agents as cisplatin rationalizes the strategy for anticancer chemotherapy. The removal of the cisplatin/DNA lesions gives the chance to the cancer cells...
5.
Slavchev I, Dobrikov G, Valcheva V, Ugrinova I, Pasheva E, Dimitrov V
Bioorg Med Chem Lett
. 2014 Sep;
24(21):5030-3.
PMID: 25248685
Aminoethyl substituted 2-endo-fenchol prepared from (-)-fenchone was used as scaffold for the synthesis of series of 31 amide structures by N-acylation applying cinnamic acids and analogues. The evaluation of their...
6.
Dobrikov G, Valcheva V, Nikolova Y, Ugrinova I, Pasheva E, Dimitrov V
Eur J Med Chem
. 2014 Mar;
77:243-7.
PMID: 24642567
The synthesis of new enantiopure N-acyl compounds derived from (-)-fenchone has been performed. The evaluation of their in vitro activity against Mycobacterium tuberculosis H37Rv showed for most of them moderate...
7.
Yusein-Myashkova S, Ugrinova I, Pasheva E
BMB Rep
. 2013 Dec;
49(2):99-104.
PMID: 24325815
The nuclear non-histone protein high mobility group box (HMGB) 1 is known to having an inhibitory effect on the repair of DNA damaged by the antitumor drug cisplatin in vitro....
8.
Dobrikov G, Valcheva V, Nikolova Y, Ugrinova I, Pasheva E, Dimitrov V
Eur J Med Chem
. 2013 Mar;
63:468-73.
PMID: 23524112
The synthesis of 22 structurally diverse urea, thiourea and acylthiourea derivatives containing the (R)-2-amino-1-butanol motif has been performed. The evaluation of their in vitro activity against Mycobacterium tuberculosis (H37Rv and...
9.
Osmanov T, Ugrinova I, Pasheva E
Biochem Biophys Res Commun
. 2013 Feb;
432(2):231-5.
PMID: 23402754
Almost all essential nuclear processes as replication, repair, transcription and recombination require the chromatin template to be correctly unwound and than repackaged. The major strategy that the cell uses to...
10.
Todorova J, Pasheva E
Oncol Lett
. 2012 Jun;
3(1):214-218.
PMID: 22740883
The high mobility group box 1 (HMGB1) protein is an abundant non-histone component of chromatin well known for its two DNA binding domains, HMG box A and HMG box B....